08 Jan, 2019 03:07 AM
- President of City of Hope National Medical Center and holds the Deana and Steve Campbell Physician-in-Chief.
- Elected President of the American Association for Cancer Research (AACR) in 2017, th...read more
21 Dec, 2018 08:53 AM
Sydney, Australia - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep“ or “the Company“) On 19 December 2018, the Company announced that it had entered into a securities purchas...read more
21 Dec, 2018 08:52 AM
With respect to the shares the subject of this issuance as detailed in the Appendix 3B lodged today, the Company gives notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (the "Corp...read more
20 Dec, 2018 08:14 AM
For the issue by the Company of 2,080,000 Warrants convertible into 208,000,000 Warrant Shares (in aggregate) at an exercise price of US$0.025 per Warrant Share.
This Prospectus has been prepared f...read more
19 Dec, 2018 03:10 PM
Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data
SYDNEY, AUSTRALIA – December 19, 2018 – Immutep Limited ...read more
17 Dec, 2018 10:00 AM
Safety, tolerability & phase 2 dose determined
Phase 2 trial first patient to be dosed early 2019
5 patients with partial responses
4 patients with stable disease
SYDNEY, Australia...read more
29 Nov, 2018 07:21 AM
SYDNEY, AUSTRALIA – November 29, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy t...read more
28 Nov, 2018 07:25 AM
SYDNEY, AUSTRALIA – November 28, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy t...read more
27 Nov, 2018 03:13 PM
SYDNEY, AUSTRALIA – November 27, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I cl...read more
